Metfomin
Phase 3Small molecule
Metfomin is one of 182 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.
4
Indications
6
Total Trials
2
Active Trials
181
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Metfomin
UUniversity of Texas Southwestern Medical Center
Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cognitive impairment1 trial
Breast Cancer1 trial
Polycystic Ovary Syndrome1 trial
The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients
Recruiting·—·Phase 3·NCT06836128·102 enrolled
Obesity1 trial
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
Completed·—·Phase 4·NCT07120828·260 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metfomin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details